Blood Podcast Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets
Nov 21, 2024
Explore a revolutionary risk classification scheme for acute myeloid leukemia patients unsuitable for intensive therapy. Discover the promising results of daratumumab combined with chemotherapy for pediatric leukemia, highlighting an impressive 80% overall response rate in T-cell acute lymphoblastic leukemia. Learn about groundbreaking research on genetically engineered platelets that remain viable under standard blood banking conditions, opening doors for innovative clinical applications. Tune in for insights that could reshape treatment strategies!
AI Snips
Chapters
Transcript
Episode notes
Four-Gene Signature Outperforms ELN For Venetoclax
- ELN 2017 and 2022 risk criteria poorly predict benefit from venetoclax plus azacitidine in older, treatment-ineligible AML patients.
- A four-gene signature (TP53, FLT3-ITD, NRAS, KRAS) better stratifies likely benefit from this regimen.
TP53 Predicts Low Benefit; Wild-Type Predicts High
- TP53-mutant patients showed very poor median overall survival (5.5 months) on venetoclax-azacitidine.
- Patients lacking TP53, FLT3-ITD, NRAS, or KRAS alterations had the best median survival (26.5 months).
Apply The Four-Gene Classifier Clinically
- Use the four-gene signature to guide research and clinical decisions for treatment-ineligible AML patients receiving venetoclax-azacitidine.
- Prioritize studies to refine optimal therapies for each benefit group identified by these genes.